About Sutro Biopharma, Inc.
Sutro Biopharma, Inc. is a publicly traded biotechnology company headquartered in South San Francisco, California focused on clinical-stage drug discovery, development and manufacturing. Using a proprietary cell-free protein synthesis platform, Sutro is working on oncology therapeutics using protein engineering and rational design. Founded in 2003 under the name Fundamental Applied Biology, the company name changed to Sutro Biopharma in 2009. William Newell, CEO as of 2024, joined Sutro in January 2009.
2BB score and signals
Sutro Biopharma, Inc.’s current 2BB score is 18 out of 100, built from the signal categories below.
| Signal | Score | Reading |
|---|
| Activity | 21 | Low |
| Momentum | 18 | Strongly Weakening |
| Financial strength | 13 | Very Weak |
| Quality | 100 | Very Strong |
| Risk | 56 | Moderate |
Company facts
| Headquarters | South San Francisco, California, United States |
| Founded | 2003 |
| Employees | 133 |
| 52-week range | $7.15 – $43.85 |
Recent earnings
| Report date | EPS actual | EPS estimate | Revenue actual | Revenue estimate |
|---|
| 2026-11-04 | — | -1.9491 | — | $10.55M |
| 2026-08-10 | — | -2.2648 | — | $13.21M |
| 2026-05-14 | -2.94 | -3.8463 | $14.52M | $8.24M |
| 2026-03-23 | -5.29 | -4.4309 | $11.65M | $8.51M |
Related companies
